Fluzoparib
Ovarian Endometrioid Adenocarcinoma
Explore 41 assets in Ovarian Endometrioid Adenocarcinoma →Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Sun Yat-sen University
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06063070CT.gov First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer | — | Not Yet Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Ovarian Endometrioid Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Fluzoparib (this asset) | Sun Yat-sen University | P2 | CCC · 53 |
| Carboplatin | National Cancer Institute (NCI) | P3 | BBB |
| Olaparib | University of Colorado, Denver | P3 | BB |
| Adriamycin | National Cancer Institute (NCI) | P3 | BB |
| Cyclophosphamide | Roswell Park Cancer Institute | P2 | BB |
| Multi-Epitope Folate Receptor Alpha-Loaded Dendritic Cell Vaccine | Mayo Clinic | P2 | BB |
| Pembrolizumab | Roswell Park Cancer Institute | P2 | BB |
| Cis-Diamminedichloroplatinum Ii | Genelux Corporation | P3 | BB |
| Cediranib | National Cancer Institute (NCI) | P3 | BB |
+42 more in the Ovarian Endometrioid Adenocarcinoma cohort
Other indications for Fluzoparib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Primary Peritoneal Carcinoma | — | P3 | B · 62 |
| Malignant Pancreatic Neoplasm | — | P3 | B · 62 |
| Breast Carcinoma | — | P3 | B · 60 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Fluzoparib in Ovarian Endometrioid Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/fluzoparib-ovarian-endometrioid-adenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →